Article

Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease.

Department of Clinical and Experimental Medicine, Federico II University Medical School of Naples, Italy.
Clinical and investigative medicine. Medecine clinique et experimentale (Impact Factor: 1.15). 01/2008; 31(1):E24-9.
Source: PubMed

ABSTRACT Non-Alcoholic Fatty Liver Disease occurs mainly in severly obese patients and its relationship to Metabolic Syndrome is increasingly recognized. The aim of this study was to determine energy production-utilization by measuring the Basal Metabolic Rate in severely obese patients, characterized by NAFLD, with or without Metabolic Syndrome. Then, the role of systemic inflammation was assessed.
Twenty severly obese men with Metabolic Syndrome were compared with a well-matched cohort of patients without Metabolic Syndrome. All showed hepatic steatosis at UltraSonography. Basal Metabolic Rate was measured by indirect calorimetry using a canopy system and single-frequency bio-impedance analysis. Serum Interleukin-6 and fibrinogen levels were measured as markers of inflammation
Basal Metabolic Rate was higher in severely obese patients with Metabolic Syndrome than in those without it: 2,496+/-358 kcal/d vs 2,126+/-253 kcal/d, P = 0 .001. Laboratory findings of concurrent chronic inflammation were also higher in these patients, i.e., Il6 4.35+/-1.34 pg/ml vs 6.23+/-2.1 pg/ml, P = 0.034; fibrinogenemia 285+/-40 mg/dL vs 376+/-91 mg/dL, P = 0.020; these of of cytonecrosis, i.e., AlaninaminoTransferase, equally behaved 32.3+/-7.9 UI vs 65.7+/-28.2 UI, P < 0.001. Visceral adiposity and arterial hypertension were more frequently detected in patients with Metabolic Syndrome.
Increased energy expenditure, observed in morbidly obese patients as a consequence of a systemic, low-grade, inflammatory process, may explain progression from obesity to Metabolic Syndrome, independent of the presence of NAFLD. In this context, increased Basal Metabolic Rate may be a clue of Metabolic Syndrome.

Download full-text

Full-text

Available from: Giovanni Tarantino, Jul 04, 2015
0 Followers
 · 
190 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The estimated prevalence of NonAlcoholic Fatty Liver Disease in the general population in western countries is about 30%, but it is higher among obese and diabetic people. It is likely that more sophisticated approaches are required to understand its pathogenesis and to develop drug targets. In the meantime, the range of associations between NAFLD and other illnesses broadens. Although association does not mean causation, the link between some diseases and NAFLD suggests a common mechanism.
    Clinical and investigative medicine. Medecine clinique et experimentale 02/2008; 31(5):E290-5. · 1.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fatty liver disease is a problem in both bariatric patients and in patients with moderate obesity. Tumor necrosis factor (TNF)-alpha has been frequently measured in nonalcoholic steatohepatitis (NASH) with or without diabetes, but less is known about interleukin (IL)-6 and IL-10. Moderately obese patients (n = 80) with histologically proven steatosis (n = 29) and NASH (n = 51) were recruited. Serum levels of cytokines were documented along with clinical information. The aim was to identify the correlates of such biomolecules in a stable population. Diabetes tended to be more associated with NASH (52.5% instead of 41.4%, P = 0.015), with no difference of age, gender, or body mass index regarding steatosis. For the entire population, cytokine changes were not significant, including TNF-alpha and IL-6. In diabetics only, all markers tended to diminish with NASH, especially IL-10 (P = 0.000). IL-10 correlated with homeostatic model assessment index (P = 0.000) and other variables of glucose homeostasis in diabetes, thus representing a major marker of the disease. (1) Generally inconsistent changes in pro- and anti-inflammatory cytokines occurred when NASH was globally compared to steatosis. (2) In contrast, downregulation of IL-6 and IL-10 was perceived in diabetics with NASH. (3) Arterial hypertension did not play a role in these circumstances. (4) IL-10 maintained strong correlations with glucose metabolism indices. (5) TNF-alpha could not be incriminated for progressive liver damage, as values failed to increase in NASH. (6) Investigations of IL-10 and other counterregulatory cytokines are lacking in this context and deserve further studies.
    Obesity Surgery 07/2010; 20(7):906-12. DOI:10.1007/s11695-010-0181-4 · 3.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-alcoholic fatty liver disease (NAFLD), a further expression of metabolic syndrome, strictly linked to obesity and diabetes mellitus, is characterized by insulin resistance (IR), elevated serum levels of free fatty acids and fatty infiltration of the liver, which is known as hepatic steatosis. Hepatocyte apoptosis is a key feature of this disease and correlates with its severity. Free-fatty-acid-induced toxicity represents one of mechanisms for the pathogenesis of NAFLD and hormones, growth factors and adipokines influence also play a key role. This review highlights the various pathways that contribute to the development of hepatic steatosis. Circulating concentrations of inflammatory cytokines are reckoned to be the most important factor in causing and maintaining IR. Low-grade chronic inflammation is fundamental in the progression of NAFLD toward higher risk cirrhotic states.
    World Journal of Gastroenterology 10/2010; 16(38):4773-83. · 2.43 Impact Factor